{"title":"Pharmacotherapy of obesity: what’s new?","authors":"E. Troshina, E. Ershova","doi":"10.14341/PROBL9315","DOIUrl":"https://doi.org/10.14341/PROBL9315","url":null,"abstract":"The lifestyle change that underlies the treatment of such a prevalent chronic disease as obesity is often insufficient to successfully clinically relevant reduce body weight, especially in the presence of comorbid conditions and diseases (type 2 diabetes, atherogenic dyslipidemia, arterial hypertension, ischemic heart disease, hyperuricemia and gout, obstructive sleep apnea syndrome, polycystic ovary syndrome and other menstrual irregularities etc.). The availability in our country until recently, only two drugs for the treatment of obesity is extremely limited choice in the case of existing contraindications to this or another drug or the appearance of any side effects. The registration in Russia in 2016 of a new drug for the treatment of obese patients, including morbid or complicated concomitant diseases and conditions, an analogue of human glucagon-like peptide-1 — liraglutide in a dose of 3.0 mg, has replenished the arsenal of obesity pharmacotherapy and substantially extended capabilities of management of obesity and overweight including patients with severe comorbidities.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"272 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122770349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Statin administration is associated with higher IGF-1 levels in patients without diabetes mellitus","authors":"O. Shpagina, I. Bondarenko, G. Kolesnikova","doi":"10.14341/PROBL8759","DOIUrl":"https://doi.org/10.14341/PROBL8759","url":null,"abstract":"Background: Research makes it clear that the IGF-1 level correlates with cardiovascular disease, chronic heart failure, and mortality. Yet, little is known about the effect of statins on IGF-1. \u0000Aims: to evaluate the effect of statin treatment on IGF-1 and its association with a cardiovascular risk. \u0000Material and methods: The study included 115 patients (mean age, 55.8±6.1 years) who either were overweight or had mild obesity (body mass index 28.6±3.8 kg/m2) without diabetes. Group 1 consisted of 70 patients with verified coronary artery disease receiving statin therapy; group 2 included 45 healthy subjects. Coronary angiography and treadmill test were used to diagnose coronary artery disease. Impaired glucose tolerance and total cholesterol, triglycerides, LPHD, LPLD, fibrinogen, and IGF-1 levels were evaluated in all the subjects. Heart chamber geometry was assessed by echocardiography. \u0000Results: The IGF-1 level was significantly higher in group 1 compared to the control group (196 and 167 ng/ml, respectively; р=0.014). Serum levels of IGF-1 were associated with duration of statin therapy (R=0.311; p=0.000), stage of hypertension (R=0.187; p=0.04), fibrinogen (R=0.274; p=0.033), TG (R=0.316; p=0.006), total cholesterol (R=–0.213; p=0.016), LPLD (R=–0.184; p=0.038), smoking (R=0.3; p=0.009), ejection fraction (R=0.298; p=0.041), end-diastolic volume (R=0.422; p=0.036), end-systolic volume (R=0.407; p=0.042), end-diastolic dimension (R=0.27; p=0.014), interventricular septal thickness (R=0.247; p=0.02), and left ventricular posterior wall thickness (R=0.258; p=0.019). Rosuvastatin dose positively correlated with the IGF-1 level (R=0.521; p=0.028). \u0000Conclusions: Statin administration is associated with higher IGF-1 levels in patients without diabetes. High IGF-1 level correlates with the risk factors of coronary artery disease: hypertension, lipid profile, and fibrinogen level and has an adverse effect on chronic heart failure by altering the cardiac remodeling.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124996140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Mokhort, N. Kolomiets, S. Petrenko, E. Fedorenko, A. Mokhort
{"title":"Dynamic monitoring of iodine sufficiency in Belarus: results and problems","authors":"T. Mokhort, N. Kolomiets, S. Petrenko, E. Fedorenko, A. Mokhort","doi":"10.14341/PROBL8686","DOIUrl":"https://doi.org/10.14341/PROBL8686","url":null,"abstract":"The strategy for elimination of iodine deficiency in the population was developed and implemented in the Republic of Belarus. It is based on acceptance of recommendations that iodized salt is a unique source of iodine support. Currently, adequate iodine consumption is achieved. The prevalence of thyroid gland diseases caused by iodine deficiency was significantly decreased. In 2013, the International Council for Control of Iodine Deficiency Disorders (ICCIDD), a global non-profit non-governmental organization established to eliminate iodine deficiency and its negative consequences, published the results of iodine status assessment in the world. According to these data, the Republic of Belarus provides adequate iodine intake. In 2016, Iodine Global Network published maps characterizing iodine supply for the two main categories — school-age children and pregnant females. These data have confirmed that the Republic of Belarus refers to countries with sufficient iodine consumption according to the results of subnational studies. Despite the achieved successes, new issues are raised: quality of iodine sufficiency monitoring, risks of excessive salt intake, and need for new approaches to diagnosing thyroid pathology due to iodine deficiency.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134184130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Spasov, Спасов Александр Алексеевич, V. Kosolapov, Косолапов Вадим Анатольевич, D. Babkov, Бабков Денис Александрович, O. Mayka, Майка Ольга Юрьевна
{"title":"Glucokinase activators — a promising class of antidiabetic drugs","authors":"A. Spasov, Спасов Александр Алексеевич, V. Kosolapov, Косолапов Вадим Анатольевич, D. Babkov, Бабков Денис Александрович, O. Mayka, Майка Ольга Юрьевна","doi":"10.14341/PROBL8747","DOIUrl":"https://doi.org/10.14341/PROBL8747","url":null,"abstract":"Type 2 diabetes mellitus is an urgent problem of the modern healthcare. Despite a wide choice of oral hypoglycemic drugs, today there is a great need to create and introduce into clinical practice new, effective, and safe drugs for the treatment of diabetes. One of the promising targets for the creation of new antidiabetics is a glucokinase. It has an exceptionally high influence on glucose homeostasis, serving as a glucose “sensor” in pancreatic β-cells and controlling the rate of glycogen synthesis in the liver. In the present work, the molecular-genetic structure of the enzyme, as well as its interrelation with the organs and tissues of the organism, is presented. The modern ideas about activators of glucokinase as a promising class of antidiabetic drugs are outlined, their hypoglycemic and general antidiabetic effects proved in preclinical and clinical studies are considered. The most advanced activators of glucokinase, undergoing clinical trials, are indicated.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124642322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a case report","authors":"E. Khramova, E. Khorosheva, O. Perfilova","doi":"10.14341/probl8636","DOIUrl":"https://doi.org/10.14341/probl8636","url":null,"abstract":"Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) is an autosomal recessive mitochondrial fatty acid beta-oxidation disorder with variable presentation including lack of energy (lethargy), low blood sugar (hypoglycemia), weak muscle tone (hypotonia), hepatic steatosis, and hypocarnitinemia. In this report, we describe a 9-month-old male patient who suffered from recurrent hypoglycemia with hypoglycemic convulsions, vomiting, and neurological regression since the age of 4 months. The patient presented with hypotonia, motor delay, hepatomegaly, protein-energy malnutrition (BMI SDS — 2.8). Biochemical tests demonstrated hypoglycemia (2.5 mmol/l), elevated lactate, creatine phosphokinase, and aminotransferases. There were also increased concentrations of long-chain acylcarnitine and 3-hydroxyacylcarnitine as well as a dramatic decrease in the carnitine level. Digestive tract malformations, endocrinopathies, and degenerative diseases of the nervous system were excluded hydroxyacyl-CoA dehydrogenase (HADHA) gene)testing revealed a homozygous mutation p.Glu474Gln. This confirmed the diagnosis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Diet correction by adding medium chain triglycerides, compensation of carnitine deficiency, and symptomatic therapy made it possible to avoid fatal metabolic crises and manage neurological regression. Early detection, diagnosis, and treatment of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency may improve clinical outcomes.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121826887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The peculiarities of self in young patients with type 1 diabetes mellitus","authors":"A. A. Fedorova, E. Shishkina, Vitaliy S. Kablukov","doi":"10.14341/probl8249","DOIUrl":"https://doi.org/10.14341/probl8249","url":null,"abstract":"The problem of the influence of self on human behavior is one of the major focuses of psychologists. However, the problem of self-identification of patients with somatic diseases, in particular type 1 diabetes mellitus, still remains poorly understood. \u0000Aim: the study aim was to investigate the characteristics of self-evaluation in young patients with type 1 diabetes mellitus. \u0000Material and methods. The theoretical and methodological basis of the study was the concept by V.V. Stolin (1985) and the theory of self by S.R. Pantileev (1989). We used the self-attitude assessment (SAA) method by S.R. Pantileev, personal differentia method adapted at the Bekhterev Research Institute; and self-esteem scale test by M. Rosenberg. The study included 60 subjects allocated into two groups: 30 patients with type 1 diabetes mellitus, a mean age of 22.5 years (18 to 25 years) and a mean disease duration of 5 years; 30 healthy subjects with a mean age of 21.5 years (18 to 25 years). \u0000Results. Patients with type 1 diabetes, unlike healthy subjects, had a low level of self-evaluation; they had the most pronounced negative emotional attitude to their Self, which reflected a low level of self-acceptance and comprise. Patients with type 1 diabetes had the level of self-esteem lower than that in healthy subjects. They were characterized by the presence of internal conflicts, disagreement with oneself, and excessive soul-searching and reflection. They considered themselves as the source of their failures. \u0000Conclusions. The results indicate the distinct differences in the structure of Self between type 1 diabetes patients and healthy subjects.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129100524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Kalinchenko, G. Chistousova, V. Petrov, E. V. Vasiliev, A. Tiulpakov
{"title":"The rare form of congenital adrenal hyperplasia caused by an autosomal dominant form of STAR deficiency","authors":"N. Kalinchenko, G. Chistousova, V. Petrov, E. V. Vasiliev, A. Tiulpakov","doi":"10.14341/probl8644","DOIUrl":"https://doi.org/10.14341/probl8644","url":null,"abstract":"The steroidogenic acute regulatory protein (StAR) is crucial for transport of cholesterol to mitochondria where biosynthesis of steroids is initiated. Loss of StAR function due to autosomal-recessive mutations in the STAR gene leads to lipoid congenital adrenal hyperplasia (LCAH) which is characterized by impaired synthesis of adrenal and gonadal steroids, which causes adrenal insufficiency, primary ovarian failure in 46XX patients, or 46XY disorder of sex development (DSD). However, there were a few reports of 46 XY DSD patients with LCAH caused by a heterozygous mutation in the STAR gene. Here, we describe another rare case of LCAH in a 46XY patient with DSD and primary adrenal insufficiency due to an autosomal-dominant mutation in the STAR gene.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116597951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Characteristics of primary hyperparathyroidism in young patients","authors":"E. Mamedova, N. Mokrysheva, L. Rozhinskaya","doi":"10.14341/probl9399","DOIUrl":"https://doi.org/10.14341/probl9399","url":null,"abstract":"Primary hyperparathyroidism (PHPT) is well studied in elderly patients. Studies of PHPT characteristics in children, adolescents, and young adults are rare. In some of these studies, investigators have compared clinical and laboratory characteristics of PHPT between young and elderly patients and revealed several differences. An early onset of PHPT may indicate familial syndromes associated with PHPT. These include: multiple endocrine neoplasia syndrome type 1, type 2A, and type 4, hyperparathyroidism-jaw tumor syndrome, familial hypocalciuric hypercalcemia, and familial isolated hyperparathyroidism. However, the need for routine genetic tests to exclude these syndromes in all patients with PHPT manifested at a young age is not obvious. To date, there are a few foreign studies on the need for genetic testing in all young patients with PHPT, but their results are controversial. Our review summarizes the data of foreign and Russian studies on characteristics of PHPT in patients with disease onset at a young age.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"10 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121005895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular genetic factors in the development of papillary thyroid cancer in the Kazakh population","authors":"M. Espenbetova, N. Glushkova, A. Krykpayeva","doi":"10.14341/probl8691","DOIUrl":"https://doi.org/10.14341/probl8691","url":null,"abstract":"Introduction. In the last decade several population studies on the association of the genes NKX2-1 and FOXE1 with sporadic papillary thyroid cancer were conducted. In the Kazakh population of similar work to date were not conducted. The aim of this study was to study the genetic association of the FOXE1 (rs9655313) and NKX2-1 (rs944289) oncomarkers with papillary thyroid cancer in the Kazakh population. \u0000Materials and methods. We conducted a case-control study that allows us to retrospectively evaluate the association of NKX2-1 and FOXE1 genes and papillary thyroid cancer. \u0000Results. The frequency distribution of FOXE1 rs965513 polymorphism in the group of papillary thyroid cancer and the control group detected by healthy individuals was significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the AA genotype (17.5%) was in three times more often compared with the control group (5.1%). The GG variant had a lower frequency in the group of persons of papillary thyroid cancer (37.9%) against the control group (61.4%), the odds ratio (OR) in the FOXE1 rs965513 group was 2.367. The distribution of the NKX2-1 (rs944289) polymorphism frequencies in the compared groups of values were significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the genotype of TT (30.5%) against the control group (20.7%) was 1.5 times more common. The SS variant had a lower frequency of occurrence in the group of persons of papillary thyroid cancer (19.8%) against the control group (28.9%), OR in NKX2-1 (rs944289) group was 1.46. \u0000Conclusion. Carrying out screening for carriers of FOXE1 rs965513 and NKX2-1 (rs944289) can become an effective means of early diagnosis with a high frequency of its spread and associations with cases of papillary thyroid cancer in the Kazakh population.","PeriodicalId":342539,"journal":{"name":"Problems of Endocrinology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126416216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}